The CCI cleared a Permira-controlled vehicle's secondary purchase of 23% to 25.71% of Cloudnine on 13 October 2026, with no price and no named seller. The only primary price for Cloudnine shares is the one Apollo filed in May.
On 13 October 2026 the Competition Commission of India approved Combination C-2026/09/1460, under which a Permira-controlled Luxembourg vehicle buys a minority stake in Kids Clinic India Limited, the Cloudnine maternity, paediatrics and fertility chain, through a secondary purchase. The parties' summary puts the stake at approximately 25.71% fully diluted; the Commission's press release says approximately 23%. Neither document gives a price or names the seller. The only primary price for Cloudnine equity is Apollo Hospitals' May 2026 filing: Apollo's Cradle and Fertility businesses, agreed to be sold to Cloudnine at an enterprise value of about INR 1,550 crore, payable in INR 765 crore of cash and a 9.9% Cloudnine stake valued at INR 785 crore. Half of Apollo's consideration is now paper whose next price a sponsor sets.
What a board member needs before the next meeting on this.
- The stake is a range until the detailed order lands. The parties' summary says approximately 25.71% on a fully diluted basis. The CCI press release of 13 October 2026 says approximately 23%. The Commission says a detailed order will follow.
- The CCI documents carry no price and name no seller. The purchase is secondary, so the money goes to existing shareholders. The CCI order on the Apollo deal names Cloudnine's controlling shareholders as Temasek's Arvon, TPG's NewQuest Asia Fund IV, True North India Fund V LLP and the founder group, but no CCI document says who is selling.
- Apollo's filing is the only primary mark on Cloudnine equity. Apollo valued its approximately 9.9% Cloudnine stake at INR 785 crore. On our arithmetic that puts the enlarged company's equity at roughly INR 7,890 crore to INR 7,970 crore. This is a share-swap mark, not the Permira price.
- Half of Apollo's exit is paper a sponsor now reprices. INR 785 crore of Apollo's INR 1,550 crore consideration, just over half on our arithmetic, arrives as Cloudnine equity and debentures. The Permira secondary puts a sponsor price on those shares, though no filing has disclosed it.
On 13 October 2026 the Competition Commission of India approved Combination C-2026/09/1460, under which NuageLux BidCo S.à r.l, a Luxembourg vehicle "ultimately controlled by Permira Holdings Limited", acquires a minority stake in Kids Clinic India Limited, which runs the Cloudnine maternity, paediatrics and fertility chain (CCI press release 68/2026-27).
The notice was filed on 1 September 2026, the day the Commission cleared Cloudnine's purchase of Apollo's Cradle and Fertility businesses (CCI register of Section 31 orders). Neither CCI document for the Permira deal gives a price or names the seller. One primary filing does price Cloudnine's shares, and a seller should read that one.
The stake is a range until the detailed order lands
The parties' summary, published by the CCI, describes the acquisition of "approximately 25.71% of the shareholding (on a fully diluted basis)" through a secondary purchase (CCI summary, C-2026/09/1460). The Commission's own press release puts the same stake at approximately 23% and says a detailed order will follow (CCI press release 68/2026-27).
The base is also moving: the Apollo transaction issues equity shares and optionally convertible debentures representing 9.9% of Cloudnine on a fully diluted basis to Apollo Health and Lifestyle Limited, and a further 2.19% to 3.90% to Temasek's Arvon Investments to raise funds for the Apollo acquisition (CCI order, C-2026/06/1436).
Read the Permira position as 23% to 25.71% until the order states its base. Because the purchase is secondary, the money goes to selling shareholders, not to Cloudnine. That order names the controlling shareholders as Arvon, TPG's NewQuest Asia Fund IV, True North India Fund V LLP and the founder group; no CCI document says which of them is selling.
Apollo's filing is the only primary price on the record
On 20 May 2026 Apollo Hospitals Enterprise told NSE and BSE that its subsidiary would sell Apollo Specialty Hospitals, which runs Apollo Cradle, and Apollo Fertility Centre to Cloudnine at an enterprise value of approximately INR 1,550 crore: INR 765 crore in cash and an approximately 9.9% stake in Kids Clinic India valued at INR 785 crore, a consideration Apollo describes as set at arm's length (Apollo Hospitals Regulation 30 disclosure, 20 May 2026).
On our arithmetic, 9.9% at INR 785 crore values all of the enlarged Cloudnine at roughly INR 7,890 crore to INR 7,970 crore of equity, the spread reflecting Apollo's "approximately". Apollo disclosed turnover of INR 351.53 crore for Apollo Specialty Hospitals and INR 100.05 crore for Apollo Fertility Centre (Apollo Regulation 30 update, 20 May 2026), so the businesses were priced at about 3.4 times that turnover on our arithmetic. That mark was agreed in a share swap between a strategic seller and a platform; it does not tell you what Permira paid.
Buying, selling or valuing a healthcare business? Talk to the principal who runs the deal. Discuss a transaction
Half of Apollo's exit is paper that a sponsor now reprices
On our arithmetic, just over half of Apollo's consideration, INR 785 crore of INR 1,550 crore, arrives as Cloudnine shares and debentures. Apollo says it will be the largest non-financial shareholder, with a nominee director on the board (Apollo press release, 20 May 2026). The value of that paper is set by what financial buyers pay, and the Permira secondary puts a sponsor price on Cloudnine equity that no filing has yet disclosed.
If the secondary price per share sits above the May mark, Apollo's stake has gained value before completion; if below, the cash half was the better half. This is what a seller misreads in a cash-and-stock exit to a consolidator: the enterprise value is fixed at signing, but the stock half is a minority position whose next price is set by investors the seller does not control.
This sponsor secondary cleared faster than the strategic merger
The Apollo combination drew two information requests and a city-by-speciality market-share review, with combined shares of 10% to 15% in dilation and curettage in Delhi-NCR and 5% to 10% in IVF and caesarean sections in several cities (CCI order, C-2026/06/1436).
It took 70 days from notice to approval on our count; Apollo gives 31 October 2026 as its indicative completion date (Apollo Regulation 30 disclosure). The Permira notice raised no horizontal overlap, only a "potential indirect and minuscule vertical relationship" through a Permira-controlled pharmaceutical company in India (CCI summary), and cleared in 42 days on our count.
The Gulf read-across is our judgement, and it is about structure
On our reading, the Cloudnine sequence shows two exit routes for a single-specialty women's and children's business: sell into a consolidating platform for part cash and part minority stock, as Apollo did, or sell a minority stake to a sponsor, as one or more Cloudnine shareholders now have.
Nothing in these filings speaks to Gulf merger control, foreign ownership or licensing, and a GCC owner should not read them as precedent for local approvals. What we think travels is the structure, and the lesson that a share-swap exit is only as good as the protections on its stock half.
Four questions before taking stock in a consolidating platform
- If half our consideration is paid in the buyer's shares, who sets the next price for those shares, and what rights do we have when a sponsor buys in below our entry mark?
- Do we have the fully diluted capitalisation table, including every convertible instrument, on the basis our percentage is calculated, and will that percentage survive the buyer's next issuance?
- Have we secured a board seat, information rights and a tag-along on any later secondary sale, as Apollo did with its nominee director?
- Which merger-control review does our buyer face, and does a strategic buyer's market-share review put our completion date at risk against a sponsor's shorter one?
Before agreeing a cash-and-stock exit, ask the buyer for the fully diluted capitalisation table with every convertible instrument, the valuation basis for the shares you receive, information rights and a tag-along on any later sponsor secondary, and a board seat. Then decide how much of the price to take in paper whose next mark someone else sets. That negotiation is sell-side work, and it is settled before signing, not after the next secondary.
Subscribe
The UAE healthcare regulatory briefing
What changed, what it reprices, and the instrument to read. Every second Tuesday. No pitches.
One email a fortnight. Unsubscribe from any of them.